title: Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial.
abstract: OBJECTIVE
  To determine whether preemptive ganciclovir therapy administered daily during antilymphocyte antibody therapy can prevent cytomegalovirus disease in renal transplant recipients who are positive for cytomegalovirus antibody.
  
  
  METHODS
  Randomized, controlled, multicenter trial.
  
  
  METHODS
  6 university-affiliated transplantation centers.
  
  
  METHODS
  113 renal transplant recipients who were positive for cytomegalovirus antibody.
  
  
  METHODS
  Patients were randomly assigned to receive either 1) ganciclovir, 2.5 mg/kg body weight administered intravenously on every day that antilymphocyte antibody therapy was administered or 2) no anticytomegalovirus therapy.
  
  
  METHODS
  Patients were observed for 6 months after completion of antilymphocyte antibody therapy for development of cytomegalovirus disease and cytomegalovirus viremia.
  
  
  RESULTS
  Cytomegalovirus disease occurred in 14% of patients (9 of 64) who received preemptive ganciclovir therapy and in 33% of controls (16 of 49) (P = 0.018). Cytomegalovirus was isolated from buffy-coat specimens from 17% of patients (11 of 64) receiving preemptive ganciclovir and from 35% of controls (17 of 49) (P = 0.03). Controlling for the reason (induction or treatment of rejection) for using antilymphocyte antibodies in a Cox proportional hazards model, we found that preemptive ganciclovir still protected against cytomegalovirus disease (adjusted relative risk, 0.27; 95% CI, 0.12 to 0.64). No adverse events were attributed to preemptive ganciclovir therapy during or within 6 months of its administration.
  
  
  CONCLUSIONS
  Preemptive ganciclovir therapy administered daily during courses of treatment with antilymphocyte antibodies reduced the excessive occurrence of cytomegalovirus disease in renal transplant recipients who were positive for cytomegalovirus antibody. This approach, which links the most potent immunosuppression to intensive antimicrobial therapy, allows preventive therapy to be given to those patients at greatest risk for developing infectious complications. These patients are likely to benefit most from the preventive strategy.
authors.affiliation: Infectious Disease Unit, Massachusetts General Hospital, Boston 02114, USA.
authors.forename: P L
authors.initials: PL
authors.lastname: Hibberd
authors.forename: N E
authors.initials: NE
authors.lastname: Tolkoff-Rubin
authors.forename: D
authors.initials: D
authors.lastname: Conti
authors.forename: F
authors.initials: F
authors.lastname: Stuart
authors.forename: J R
authors.initials: JR
authors.lastname: Thistlethwaite
authors.forename: J F
authors.initials: JF
authors.lastname: Neylan
authors.forename: D R
authors.initials: DR
authors.lastname: Snydman
authors.forename: R
authors.initials: R
authors.lastname: Freeman
authors.forename: M I
authors.initials: MI
authors.lastname: Lorber
authors.forename: R H
authors.initials: RH
authors.lastname: Rubin
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000914:Antibodies, Viral / Q000097:blood*; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D003587:Cytomegalovirus / Q000276:immunology* / Q000302:isolation & purification; D003586:Cytomegalovirus Infections / Q000517:prevention & control*; D005260:Female; D015774:Ganciclovir / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D014766:Viremia / Q000517:prevention & control
chemical_list: D000914:Antibodies, Viral; D000961:Antilymphocyte Serum; D015774:Ganciclovir